Louvain-la-Neuve, Belgium, May 12 2017 - IBA, the world's leading provider of proton therapy solutions for the treatment of cancer, announces the delivery of its first large-field-of-view Cone Beam CT (CBCT) system at the Willis Knighton Health System, Shreveport, Louisiana in readiness for commissioning.
With its large-field-of-view CBCT, IBA is the only proton therapy provider able to obtain volumetric imaging at isocenter with a field of view of 50 cm. The previous standard was 26cm. This improvement will further improve patient positioning and thus the precision of treatment. Furthermore, it enables unique opportunities for adaptive therapy by improved tracking of the proton path, starting from the patient skin through to the target tumor volume. This is especially useful for indications such as breast and pelvis.
The large-field-of-view capability is now available on IBA's Proteus®ONE** and Proteus®PLUS* solutions, and will be also installed at the following centers; Texas Center for Proton Therapy, Beaumont Health System, Baptist Health South Florida, and Groningen Proton Therapy Center.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Frederic Genin, Chief Product & Marketing Officer Proton Therapy at IBA added: "Offering solutions that have clinical meaning and help our customers in their daily lives is IBA's number one priority."
Dr Lane Rosen, Medical Director at Willis-Knighton Cancer Center commented: "IBA is recognized as a company that listens to its customers. With the latest large field of view onboard CBCT scan, they have achieved a technological advancement with an easy workflow that helps to provide greater precision for patients at WKHS and other centers."
CBCT imaging with a large-field-of-view is the first step of many planned developments in imaging; further consolidating IBA's leadership role in every aspect of radiation therapy.
*Proteus®ONE is the brand name of a configuration of the Proteus®235 in the US and Europe and a certified product in Japan.
**Proteus®PLUS is the brand name of a configuration of the Proteus®235.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
About Willis-Knighton Cancer Center
The Willis-Knighton Health System, headquartered in Shreveport, Louisiana, is a not-for-profit community healthcare corporation with four general acute care hospitals and affiliate relationships with several rural hospitals. It is the largest nongovernmental employer in the region, employing more than 6,500 people. Specialized centers of excellence include the Willis-Knighton Cancer Center, WK Proton Therapy Center, Willis-Knighton Heart & Vascular Institute, and the WK Rehabilitation Institute, a hospital that incorporates both physical and behavioral rehabilitation. Women's and children's services include maternal/fetal medicine, NICU, and PICU.
